An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Pinciroli, Patrizia ^a   Alberti, Chiara ^a   Sensi, Marialuisa ^a   Canevari, Silvana ^a   Tomassetti, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bioinformatics; Epithelial ovarian cancer; Growth factor; IL6; Microarrays

Indexed keywords

EARLY GROWTH RESPONSE FACTOR; INTERLEUKIN 6;

ADVANCED CANCER; ARTICLE; BIOINFORMATICS; C5AR1 GENE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FPR1 GENE; G0S2 GENE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE STRUCTURE; GENETIC ASSOCIATION; HUMAN; IL6 GENE; IL8 GENE; IN VITRO STUDY; KLF2 GENE; MALIGNANT TRANSFORMATION; MMP19 GENE; NEGATIVE FEEDBACK; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PATHOLOGY; SIGNAL TRANSDUCTION; THBD GENE; THROMBOSIS;

CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; THROMBOSIS; TRANSCRIPTOME;

EID: 84880905633     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-508     Document Type: Article

References (43)

1. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428. 10.1038/nrc2644, 2814299, 19461667.
2. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res 2012, 72:2701-2704. 10.1158/0008-5472.CAN-11-3911, 22593197.
3. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006, 247:4-21. 10.1016/j.mce.2005.09.014, 16297528.
4. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011, 11:719-725. 3380637, 21941283.
5. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592. 10.1158/0008-5472.CAN-06-2941, 2679985, 17234767.
6. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434. 10.1158/0008-5472.CAN-10-1496, 21123455.
7. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123. 10.1016/j.canlet.2010.02.019, 20236757.
8. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011, 9:1658-1667. 10.1158/1541-7786.MCR-11-0271, 3243808, 21976712.
9. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800. 10.1158/0008-5472.CAN-05-0623, 1534114, 16322225.
10. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464. 10.1084/jem.20090207, 2715087, 19564351.
11. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888. 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R, 8137215.
12. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011, 11:210. 10.1186/1471-2407-11-210, 3118896, 21619709.
13. Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek F, Duan Z. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010, 16:5759-5769. 10.1158/1078-0432.CCR-10-1095, 20699329.
14. Dijkgraaf EM, Welters MJ, Nortier JW, Van der Burg SH, Kroep JR. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 2012, 18:3816-3827. 10.2174/138161212802002797, 22591418.
15. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012, 31:4139-4149. 10.1038/onc.2011.572, 22158046.
16. Castellano G, Reid JF, Alberti P, Carcangiu ML, Tomassetti A, Canevari S. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res 2006, 66:10709-10719. 10.1158/0008-5472.CAN-06-1327, 17090524.
17. Degl'Innocenti D, Alberti C, Castellano G, Greco A, Miranda C, Pierotti MA, Seregni E, Borrello MG, Canevari S, Tomassetti A. Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS One 2010, 5:e12701. 10.1371/journal.pone.0012701, 2943897, 20877637.
18. Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, De SG, Bersani I, Avanzi G, Tomassetti A, Canevari S, Anichini A. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol 2011, 131:2448-2457. 10.1038/jid.2011.218, 21796150.
19. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008, 14:5198-5208. 10.1158/1078-0432.CCR-08-0196, 18698038.
20. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, DeFazio A, Chenevix-Trench G, Bowtell DD. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008, 6:1678-1690. 10.1158/1541-7786.MCR-08-0193, 19010816.
21. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 19;439:353-357.
22. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. 10.1038/nature10166, 3163504, 21720365, Cancer Genome Atlas Research Network.
23. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009, 15:2448-2455. 10.1158/1078-0432.CCR-08-2430, 3050629, 19318476.
24. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007, 25:517-525. 10.1200/JCO.2006.06.3743, 17290060.
25. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 2010, 5:e9615. 10.1371/journal.pone.0009615, 2837379, 20300634.
26. The Genecards database http://www.genecards.org. 2012.Ref Type: Generic.
27. Shahzad MM, Arevalo JM, Rmaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285:35462-35470. 10.1074/jbc.M110.109579, 2975170, 20826776.
28. The Ingenuity Pathway Analysis Software 2012, http://www.ingenuity.com.
29. The Gene Set Enrichment Analysis software 2012, http://www.broad.mit.edu/gsea.
30. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007, 39:503-512. 10.1038/ng1987, 17322878.
31. Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K, Yumoto N, Hatakeyama M. Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J Biol Chem 2007, 282:4045-4056.
32. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, Poy G, Perantoni AO, Cam M, Malik K, Lee SB. Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 2007, 282:16278-16287. 10.1074/jbc.M700215200, 17430890.
33. Delassus GS, Cho H, Hoang S, Eliceiri GL. Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol 2010, 224:549-558. 10.1002/jcp.22157, 20432456.
34. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, Oggioni M, Bertuletti N, Ditto A, Raspagliesi F, Pilotti S, Pierotti MA, Canevari S, Schneider C. Gene expression profiling of advanced ovarian cancer: characterization of molecular signature involving the fibroblast growth factor 2. Oncogene 2004, 23:8171-8183. 10.1038/sj.onc.1207979, 15377994.
35. NF-kB Target Genes http://www.bu.edu/nf-kb/gene-resources/target-genes.
36. Qi L, Higgins SP, Lu Q, Samarakoon R, Wilkins-Port CE, Ye Q, Higgins CE, Staiano-Coico L, Higgins PJ. SERPINE1 (PAI-1) is a prominent member of the early G0 → G1 transition "wound repair" transcriptome in p53 mutant human keratinocytes. J Invest Dermatol 2008, 128:749-753. 10.1038/sj.jid.5701068, 2654242, 17882266.
37. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009, 106:4519-4524. 10.1073/pnas.0900780106, 2649208, 19251651.
38. Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2012, 2:311-319. 10.1158/2159-8290.CD-12-0018, 3351275, 22576208.
39. Masoumi MS, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012, 31:143-162. 10.1007/s10555-011-9337-5, 3350632, 22101807.
40. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443. 10.1097/PAS.0b013e3181cf3d79, 2841791, 20154587.
41. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 2012, 23:311-319. 10.1097/EDE.0b013e3182456ad3, 3454462, 22252409.
42. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009, 8:683-688. 10.4161/cc.8.5.7703, 2840625, 19221481.
43. The Cancer Genome Atlas database [https://tcga-data.nci.nih.gov/] 2012.